Hormonal
Once-weekly subcutaneous semaglutide 2.4 mg significantly improves cardiometabolic risk factors (waist circumference, blood pressure, fasting plasma glucose, insulin, and lipids) in adults with overweight or obesity without diabetes compared to placebo.
If you have overweight or obesity without diabetes, once-weekly semaglutide 2.4 mg, combined with lifestyle changes, significantly improves key health markers like blood pressure, blood sugar, and cholesterol compared to placebo. These benefits require continued use, as stopping the medication leads to a reversal of these improvements.
In STEP 1, reductions in waist circumference, SBP, DBP, FPG, fasting serum insulin, lipids and HOMA-IR were greater with semaglutide versus placebo (p ≤ .001).
Why this rating
Based on two large, phase III, double-blind, placebo-controlled randomized trials (STEP 1 and 4) with over 2,700 participants.
Source
Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: <scp>STEP</scp> 1 and 4 exploratory analyses
Mikhail Kosiborod et al. · Diabetes Obesity and Metabolism · 2022
DOI 10.1111/dom.14890
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →